LivaNova (NASDAQ:LIVN) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued on Thursday.
According to Zacks, “LivaNova PLC is a medical technology company which focuses on providing treatment for cardiovascular diseases and neuromodulation. The Company’s operating units consists of Cardiac Rhythm Management, Cardiac Surgery and Neuromodulation. LivaNova PLC, formerly known as Cyberonics, Inc., is based in London, United Kingdom. “
Other analysts have also recently issued research reports about the stock. BTIG Research reaffirmed a “hold” rating on shares of LivaNova in a research note on Tuesday, November 7th. Piper Jaffray Companies reaffirmed a “buy” rating and set a $85.00 price objective on shares of LivaNova in a research note on Friday, November 3rd. Canaccord Genuity reaffirmed a “hold” rating and set a $71.00 price objective on shares of LivaNova in a research note on Wednesday, September 20th. Jefferies Group upped their price objective on shares of LivaNova from $76.00 to $80.00 and gave the company a “buy” rating in a research note on Friday, September 15th. Finally, ValuEngine cut shares of LivaNova from a “buy” rating to a “hold” rating in a research note on Wednesday. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and five have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus price target of $79.71.
LivaNova (NASDAQ:LIVN) last announced its quarterly earnings data on Thursday, November 2nd. The company reported $0.93 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.76 by $0.17. LivaNova had a net margin of 4.63% and a return on equity of 9.33%. The company had revenue of $309.70 million during the quarter, compared to analysts’ expectations of $301.22 million. During the same quarter in the prior year, the company earned $0.78 EPS. LivaNova’s revenue was up 4.9% compared to the same quarter last year. equities analysts expect that LivaNova will post 3.24 earnings per share for the current year.
In other news, Director Hugh M. Morrison sold 1,830 shares of the stock in a transaction that occurred on Wednesday, November 29th. The shares were sold at an average price of $88.00, for a total value of $161,040.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Daniel Jeffrey Moore sold 1,000 shares of the stock in a transaction that occurred on Wednesday, November 15th. The shares were sold at an average price of $81.39, for a total transaction of $81,390.00. The disclosure for this sale can be found here. In the last three months, insiders sold 6,830 shares of company stock valued at $569,350. Corporate insiders own 0.28% of the company’s stock.
Several institutional investors have recently bought and sold shares of LIVN. Shelton Capital Management purchased a new position in shares of LivaNova during the 3rd quarter worth approximately $209,000. Pura Vida Investments LLC boosted its position in shares of LivaNova by 10.2% during the 3rd quarter. Pura Vida Investments LLC now owns 154,273 shares of the company’s stock worth $10,808,000 after purchasing an additional 14,271 shares during the period. California Public Employees Retirement System boosted its position in shares of LivaNova by 2.5% during the 3rd quarter. California Public Employees Retirement System now owns 149,307 shares of the company’s stock worth $10,460,000 after purchasing an additional 3,641 shares during the period. Janney Montgomery Scott LLC boosted its position in shares of LivaNova by 248.7% during the 3rd quarter. Janney Montgomery Scott LLC now owns 12,916 shares of the company’s stock worth $905,000 after purchasing an additional 9,212 shares during the period. Finally, Jane Street Group LLC purchased a new position in shares of LivaNova during the 3rd quarter worth approximately $611,000. 86.00% of the stock is owned by institutional investors and hedge funds.
LivaNova PLC is a medical device company focused on the development and delivery of therapeutic solutions. The Company’s segments include Cardiac Surgery, Cardiac Rhythm Management, Neuromodulation and Other. The Cardiac Surgery segment is engaged in the development, production and sale of cardiovascular surgery products.
What are top analysts saying about LivaNova? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for LivaNova and related companies.